No Data
No Data
Express News | Aprea Therapeutics To Host Virtual KOL Event On APR-1051
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
DOYLESTOWN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic
Maxim Group Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $16
Maxim Group analyst Jason McCarthy maintains $Aprea Therapeutics(APRE.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 0.0% a
H.C. Wainwright Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright analyst Joseph Pantginis maintains $Aprea Therapeutics(APRE.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of
Express News | Aprea Therapeutics Doses First Patient In Phase 1 ACESOT-1051 Study Of Oral WEE1 Inhibitor APR-1051 As Monotherapy For Advanced Solid Tumors
Express News | Aprea Therapeutics Inc: Plan to Provide a Clinical Update by Year-End 2024 and Generate Preliminary Efficacy Data During 2025
No Data